The DNMT3A R882 mutation is a known hotspot, and MDS patients harboring this mutation exhibit more severe leukopenia, frequent co-mutations in SRSF2 and IDH2, a higher frequency of excess blasts, a markedly increased rate of progression to AML, and inferior progression-free-survival (PFS) compared to non-R882 mutant MDS cases [73]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.